Search for content, post, videos

Novo Nordisk acquires Prothena’s ATTR amyloidosis programme

Marcus Schindler
The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associat
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.